Skip to main content

Press Releases

Press Release RSS Feed (opens in new window)
Press release year list 2020 2019 2018 2017 2016
11/16/2020
Tetra Bio-Pharma Provides Update on Recent Milestones
11/04/2020
Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003
11/02/2020
Tetra Bio-Pharma Inc. Acquires Common Shares of Mondias Natural Products Inc.
10/28/2020
Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.
10/22/2020
Tetra Bio-Pharma, Targeted Pharmaceutical et l'Université George Mason établissent un partenariat sur ARDS-003 pour prévenir et traiter la COVID-19
10/22/2020
Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19
10/21/2020
Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx
10/20/2020
Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury
10/07/2020
Tetra Bio-Pharma Unveils its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio
09/30/2020
Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability
09/17/2020
Tetra Bio-Pharma Adds Two Board Members and Appoints New COO
09/11/2020
Tetra Bio-Pharma Appoints Chief Financial Officer
09/04/2020
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy
09/02/2020
Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated
08/27/2020
Tetra Bio-Pharma Announces Data on its CBD Metabolite Study in Humans
08/18/2020
Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003
08/17/2020
Tetra Bio-Pharma and Mondias Enter Into Final Agreement For The Purchase Of Lumiera Health Innovation Inc.
08/07/2020
Tetra Bio-Pharma Virtually Opens the Market
08/06/2020
CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities
07/30/2020
Tetra Bio-Pharma Announces Expected Effective Date of Listing on TSX of its Common Shares and Warrants
07/28/2020
Tetra Bio-Pharma’s Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities
07/27/2020
Tetra Bio-Pharma Provides Management Update on Pharma Focus
07/23/2020
Tetra and Mondias jointly announce the acquisition of Tetra's subsidiary, Lumiera, by Mondias to create a new growth platform
07/16/2020
FDA Provides Positive Feedback on Tetra Bio-Pharma's Pre-Investigational New Drug Application for ARDS-003 to Be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome (ARDS)
07/15/2020
Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX
07/09/2020
Tetra Bio-Pharma Appoints Steve Edgett As A Strategic Advisor
06/25/2020
Tetra Bio-Pharma Announces Stock Option Grant
06/22/2020
Tetra Bio-Pharma Announces Change to its Board of Directors
06/17/2020
Tetra Bio-Pharma's Management Provides Regulatory Update of ARDS-003 for the Potential Prevention and Treatment of Cytokine Release Syndrome
06/05/2020
Tetra Bio-Pharma's Pleased to Announce Advancement of QIXLEEF(TM) and CAUMZ(TM) Clinical Trials Ahead of Annual General Meeting
06/04/2020
Tetra Bio-Pharma and Storz & Bickel Enter into Commercial Sales Agreement for the Mighty Medic Vaporizer
06/03/2020
Tetra Bio-Pharma and Altus Formulation Form New Company "TALLC" to Exploit TA-A001
06/02/2020
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA
05/26/2020
Tetra Bio-Pharma Announces Foreign Patent and Reinforces its Ophthalmic IP Portfolio with a New Australian Patent
05/22/2020
Tetra Bio-Pharma Announces Closing of Public Offering
05/15/2020
Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"
05/15/2020
Deux compagnies Québécoises unissent leurs forces afin de rendre disponible un masque haute performance pour nos Anges Gardiens
05/15/2020
Tetra Bio-Pharma Announces Sizing of Public Offering
05/14/2020
Tetra Bio-Pharma Announces Overnight Marketed Offering
05/13/2020
Tetra Announces Resignation of President
05/11/2020
Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program
05/11/2020
Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study
05/08/2020
Tetra Bio-Pharma Engages energi PR as its Public Relations Firm
05/06/2020
Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program
04/27/2020
Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome
04/27/2020
Tetra Bio-Pharma annonce qu'un de ces médicaments en recherche a le potentiel d'influencer la gestion du syndrome de libération des cytokine
04/22/2020
Tetra Expands on its Orphan Drug Development Program and Management Update
04/16/2020
Tetra Receives its 4th FDA Orphan Drug Designation
04/15/2020
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
04/14/2020
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License
04/08/2020
Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
04/06/2020
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011
04/02/2020
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF
04/01/2020
Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities
03/30/2020
Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A
03/26/2020
Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial
03/23/2020
Tetra Bio-Pharma Provides Management Update on COVID-19
03/06/2020
Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm
03/05/2020
Tetra Bio-Pharma Announces Exercise of Over-Allotment Option in Connection with Bought Deal Financing
02/27/2020
Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific
02/25/2020
Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA
02/24/2020
Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA
02/20/2020
Tetra Bio-Pharma Inc. Announces Listing of Warrants
02/20/2020
Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs
02/18/2020
Tetra Bio-Pharma Appoints Sylvain Chrétien as President
02/13/2020
Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011
02/13/2020
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
02/03/2020
Tetra Bio-Pharma Announces CAUMZ Program Update AND Expansion of Market Potential Following Type B Meeting with USA FDA
01/31/2020
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™
01/28/2020
Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003
01/27/2020
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
01/22/2020
TETRA BIO-PHARMA - PRESS RELEASE CORRECTION
01/21/2020
Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering
01/20/2020
Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
01/17/2020
Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health Canada
01/13/2020
Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF